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Abstract
Aims: To investigate candidate genes in peripheral blood
mononuclear cell (PBMC) that are associated with early
onset severe preeclampsia (ES-PE) and to describe can-
didate genes function using microarrays and real-time
polymerase chain reaction (PCR).
Methods: PBMC RNA was extracted from six patients
with ES-PE and five uncomplicated pregnancies. The
HG_U133 plus 2.0 Affymetrix GeneChips that represent-
ed 47,000 genes were used to measure gene expression
in each sample. Significance analysis of microarray iden-
tified potential signature genes characterizing ES-PE vs.
uncomplicated pregnancies. Eight genes were selected
for confirmation by real-time PCR of 32 patients with
ES-PE and 24 uncomplicated pregnancies, matched for
maternal age, parity, race and gestational weeks.
Results: Using a whole-genome approach to study the
molecular determinants of ES-PE, 72 genes were found
to be differentially expressed between cases and con-
trols, including 38 up-regulated genes and 34 down-
regulated genes in the group of ES-PE. Killer cell
immunoglobulin-like receptor, three domains, long cyto-
plasmic tail, 2 (KIR3DL2), aldo-keto reductase family 1,
member C3 (AKR1C3), churchill domain containing 1
(CHURC1), and solute carrier family 25, member 13
(SLC25A13) were validated to be down-regulated in the
patients with ES-PE by real-time PCR.
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Conclusions: Expression of genes with diverse function
is associated with ES-PE risk, providing opportunities for
the development of non-invasive diagnosis.
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Introduction
Preeclampsia (PE) is a common pregnancy-specific
syndrome (3–5%) of first pregnancies, and ranks among
the leading causes of maternal and perinatal morbidity
and mortality (12%) worldwide w7x. According to whether
the clinical manifestations occur before or after 32 weeks
of gestation, PE was classified into early and late onset
type w15x. Large epidemiological studies have demon-
strated that women with a history of early onset severe
preeclampsia (ES-PE) show an increase risk of cardio-
vascular disease w2x. The likelihood that PE will recur is
almost 50% for ES-PE w4x, whereas it is 10%–20% for
PE near term w3x. The ES-PE is regarded as more dan-
gerous than late onset severe PE and of a different eti-
ology. Despite the urgent need to diagnose PE early and
to have a non-invasive tool for prognosis and treatment
monitoring, no predictive test is available to identify preg-
nant women who will subsequently develop PE and
which of those may develop the early or late type of the
syndrome. Thus a standardized blood-based test capa-
ble of detecting individuals at risk for ES-PE would rep-
resent a major advance in clinical care.
Microarray studies of disease have been based on
RNA derived from biopsy/tissue samples. The systematic
study of the gene expression patterns of placenta
revealed differences in gene expression patterns asso-
ciated with preeclampsia w12x. However, blood samples
are less invasive, allow for a larger sample size, and make
feasible repeated sampling to monitor disease progres-
sion. Several studies have shown that total RNA derived
from circulating blood can distinguish between control
subjects and patients with various disease types w6x.
Fetal DNA or RNA testing of preeclampsia is being inves-
tigated however, and their clinical utility is still unclear.
In this study, we analyzed blood cell-derived RNA for
patterns of differential gene expression of Chinese Han
population that could serve as indicators of normal
and abnormal biological processes and provide informa-
tion on mechanisms of ES-PE.
610 Sun et al., Gene expression profiling of early onset severe preeclampsia
Article in press - uncorrected proof
Materials and methods
Subjects and sample acquisition
Informed consent was obtained from each subject in accor-
dance with the protocol approved by the Human Studies Com-
mittee of Beijing Obstetrics and Gynecology Hospital, Capital
Medical University. Maternal blood samples from 67 singleton
pregnancies (38 ES-PE and 29 uncomplicated pregnancies con-
trols) were collected between September 2006 and October
2008. We randomly selected 6 ES-PE and 5 controls to perform
oligonucleotide array. After that, the remaining 32 ES-PE and 24
controls were used as samples to validate gene expression
using real-time PCR. ES-PE was defined as new onset hyper-
tension (systolic blood pressure G160 mm Hg or diastolic blood
pressure G110 mm Hg at least twice 6 h apart) and proteinuria
(2 g per 24-h period or 2–4q on random urine dipstick in the
acute setting) after 20 weeks of gestation with severe criteria
according to guidelines published by the American College of
Obstetricians and Gynecologists in women who required deliv-
ery between 24 and 32 gestation weeks because of PE w1x. The
control group comprised healthy pregnant women in gestational
weeks 24–32 recruited during a routine visit to an antenatal clin-
ic. Only those whose pregnancy continued normally and resulted
in a full-term delivery of a healthy child with normal weight were
included in the study. Only women with the aforementioned cri-
teria within their first pregnancies were included. Women with a
concurrent diagnosis of an upper urinary tract infection, chronic
hypertension (hypertension before the 20th week of gestation),
diabetes mellitus, or pre-exiting renal disease were not included.
None of the control had a family history of PE.
RNA extraction and microarray procedures
Blood samples (8 mL) were drawn into EDTA Vacutainer tubes
(Becton Dickinson) by routine venipuncture, put immediately on
48C) and transferred to the laboratory within 2 h for blood pro-
cessing. Total RNA was isolated from lymphocytes with Trizol
(Invitrogen, Carlsbad, CA) following the manufacturer’s protocol.
The RNA preparations were then DNase treated and purified
with the RNeasy Mini Kit (Qiagen, Valencia, CA). RNA quality
was assessed on an Agilent 2100 Bioanalyzer RNA 6000
NanoChip (Agilent, Palo Alto, CA), and quantity was determined
by absorbance at 260 nm in a Beckman Coulter DU640 spectro-
photometer. With 2.5 mg of purified total RNA, samples were
prepared for cRNA amplification and hybridization, as previously
described w18x. Microarray analysis was performed overnight by
using high-density human genome U133 plus 2.0 GeneChips
(HG-U133 plus 2.0; Affymetrix, Santa Clara, CA). HG-U133 plus
2.0 GeneChip contains 54,646 25-mer probe sets, represents
about 47,000 genes. Subsequently, the chips were scanned
with an Affymetrix GeneChip Scanner 3000, and the data
were extracted by GeneChip Operating software Version
1.4(GCOS1.4) (Affymetrix Inc.). Signal intensities were centered
to the 50th percentile of each chip, and for each individual probe
set, to the median intensity of each specific subset first, to min-
imize possible technical bias, and then to the whole sample set.
Only genes identified by the GCOS software as ‘‘present’’ or
‘‘marginal’’ in all samples were analyzed.
Microarray data analysis
Raw data without normalization were analyzed by significance
analysis of microarrays (SAM). Normalized data were first filtered
to eliminate the genes which were absent in all experimental
conditions and replicates. Then, parametric analysis assuming
unequal variance was applied to test statistical significance.
Fold-ratios were derived by comparing normalized data between
controls and preeclampsia. Only genes that are up- or down-
regulated more than two-fold were filtered. Genes were deemed
statistically different between groups if they had an adjusted
P-0.05 and an average fold-change difference of)2. Average-
linkage hierarchical clustering analysis using centered correla-
tion analysis and visualization was performed using the
CLUSTER and TREEVIEW programs.
Go classification
Gene ontology analysis was performed using an online data
base known as the Molecular Analysis System (MAS, http://
bioinfo.capitalbio.com/mas/). Molecular functions, biological
processes and biological pathways up/down-regulated by ‘‘sig-
nature’’ genes of the ES-PE were identified and the statis-
tical significance of up/down-regulation was quantified by a
random overlapping P-value using the binomial test with all the
genes represented by the AffymetrixHG-U133 plus 2.0 micro-
arrays as the reference list. From the 38 blood genes over-
expressed and 34 blood genes under-expressed in ES-PE, we
selected a set of 8 genes to be evaluated by quantitative real-
time RT-PCR. We used the following criteria to make our selec-
tion: P, fold change, discrimination power form ROC curve
analysis between ES-PE patients and the control group, and the
function of the gene.
Design of specific primers
Oligonucleotide primers specific for down-regulated genes killer
cell immunoglobulin-like receptor, three domains, long cytoplas-
mic tail, 2 (KIR3DL2), aldo-keto reductase family 1, member C3
(AKR1C3), churchill domain containing 1 (CHURC1), solute car-
rier family 25, member 13 (SLC25A13) and up-regulated genes
calponin2 (CNN2), V-set and immunoglobulin domain containing
4 (VSIG4), matrix metallopeptidase 8 (MMP8), proteasome 26S
subunit ATPase 5 (PSMC5) isoforms were designed using Primer
Express Version 2.0 software (PE Applied Biosystems, Inc.,
Foster City, CA). Beta-actin is chosen as an endogenous control/
reference. Sequences of the primer sets used for real-time
PCR verification are listed in Table 1.
Validation of gene expression data by
quantitative RT-PCR
The remaining 32 ES-PE and 24 controls were enough to per-
form SYBR Green I real-time PCR assay validation. First-strand
cDNA was synthesized from 8 mg of total RNA using the ABI
High Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems, Foster City, CA) on a Perkin-Elmer (Wellesley, MA) DNA
Thermal Cycler according to the manufacturer’s protocol. The
resulting cDNA was subjected to a 40-cycle PCR amplification
followed by real-time PCR reaction using the Power SYBR
Green PCR Master Mix Kit protocol (Applied Biosystems,
P/N4367659). Four replicates were run for each gene for each
sample in a final volume of 20 mL, and multiple negative water
blanks were included in every analysis. Amplification efficiency
and specificity of the primer pairs were determined using serial
dilution of reference cDNA generated from a normal blood RNA
pool with confirmation on agarose gel to ensure that the values
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Table 1 Primer pairs used for real-time PCR validation.
Gene Forward primer Reverse primer Amplicon (bp)
AKR1C3 TGTGCCTTGGCAAAAAAGC GGTAGCGCAGGGCAATCA 54
CHURC1 TGCCTGGAGAATGGATCTTTCT AAAATCCCGCTTACTGCACACT 65
KIR3DL2 AGGGCCCCTGCTGAAATC GCTCAAACATGACATCTGACCAA 64
SLC25A13 GGGATCTACAAGGGTGCCAAA GGAAAGTAGATGGCCGAGAAAG 64
b-actin TACGCCAACACAGTGCTGTCT TGCATCCTGTCGGCAATG 70
VSIG4 TGGATGACCGGAGCCACTAC ACTTGGTTGCCATCAGGAGTCT 60
CNN2 GAAGGGCCTGAAGGATGGA GAGCCCGGCTGTAGCTTGT 59
MMP8 CCCAACTATGCTTTCAGGGAAA GCCTGAATGCCATCGATGT 67
PSMC5 CGAGAACGGCGAGTCCAT TGACCTTGGCTACTGCCATCT 57
Table 2 Clinical characteristics of early onset severe preeclampsia and normal control subjects.
Normal Early onset severe P-value
pregnancies pre-eclampsia
(ns29) (ns38)
Maternal age (years) 28.2"2.58 30.0"2.83 0.304
Body height (m) 1.62"0.06 1.60"0.05 0.481
Prepregnancy body weight (kg) 58.3"3.47 60.7"2.67 0.421
Prepregnancy BMI (kg/m2) 22.0"1.38 23.4"1.20 0.094
Gestational age at onset of preeclampsia (weeks) – 27"3.12
Gestational age at delivery (weeks) 38.6"1.14 29.5"1.87 0.000
Systolic blood pressure (mm Hg) – 173"12
Diastolic blood pressure (mm Hg) – 112"8
Infant birth weight (g) 3750"199 1650"385 0.000
Values are expressed as mean"SD and were analyzed with one-way analysis of variance; significant at P-0.05. BMIsbody mass
index.
were within linear range and the amplification efficiency was
approximately equal for each of the target gene tested. SYBR
Green PCR assays were performed on cDNA samples in 96-well
optical plates in an ABI PRISM 7300 Sequence Detection Sys-
tem (Applied Biosystems, Foster City, CA). Analysis of relative
gene expression data was performed using the comparative CT
method (DDCT) with b-actin (ACTB) as an endogenous control/
reference assay. Cycling parameters for a two-step PCR were
958C for 10 min, 1 cycle, then 608C for 1 min, 958C for 15 s, 40
cycles. The confirmation of specific amplification and lack of
primer dimmer formation were determined by calculatedmelting
dissociation curve. The real-time PCR products were examined
in 2% agarose gel.
Statistical analysis
All values are expressed as mean"SD. Statistical significance
(defined as P-0.05) of clinical characteristics of ES-PE and nor-
mal control subjects was evaluated using one-way analysis of
variance. P-values of different gestational weeks (-28 gestation
weeks and 28–32 gestation weeks) were calculated by Fisher’s
Exact test. All statistical analyses were performed with SPSS
12.0 (SPSS Inc, Chicago, IL).
Results
Gene expression signature of early onset severe
preeclampsia in peripheral leukocytes
Patients were recruited from among those who presented
with ES-PE of Beijing Obstetrics and Gynecology Hos-
pital. To explore whether we can identify a gene expres-
sion signature of ES-PE from peripheral blood samples,
38 patients and 29 controls were analyzed in this study.
Six patients and five controls were analyzed using the
Affymetrix HG-U133 plus 2.0 chips representing 47,000
individual human genes, which showed significant differ-
ences in the expression levels of 72 genes. The demo-
graphic and pregnancy characteristics of each group are
summarized in Table 2. Patients with ES-PE and controls
were similar in maternal age, pre-pregnancy body mass
index, parity, and race. All subjects were of Chinese Han
origin. According to different gestational weeks, we
classified ES-PE into two groups: -28 gestation weeks
(ns10, 26.4%) and 28–32 gestation weeks (ns28, 73.6%).
The high risk of hypoproteinemia, high blood viscosity,
proteinuria )5 g, abnormal renal function, thrombocy-
topenia, placental abruption, peritoneal fluid, fetal growth
restriction, neonatal asphyxia and neonatal death were
observed in the group of -28 gestation weeks (P-0.05,
data not shown).
Using SAM analysis, 72 genes were differentially
expressed between case and control groups based on
the following criteria: (1) false discovery rate (FDR)
-5.4%; (2) average fold change)2.0. Thirty-eight genes
were over-expressed and 34 genes were under-
expressed in the patient group (Table 3). We also did
cluster analysis on the 72 genes to arrange the samples
according to similarities in gene expression patterns as
described previously. Hierarchical cluster analysis of the
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Table 3 List of genes, up- or down-regulated by a factor of at least 2.0 between ES-PE and controls.
Original source file data
Probe set ID Gene name Describe
Down-regulation, -0.5
206529_x_at SLC26A4 solute carrier family 26, member 4
205573_s_at SNX7 sorting nexin 7
230720_at RNF182 ring finger protein 182
206632_s_at APOBEC3B apolipoprotein B mRNA editing enzyme, catalytic
polypeptide-like 3B
206881_s_at LILRA3 leukocyte immunoglobulin-like receptor, subfamily A
218638_s_at SPON2 spondin 2, extracellular matrix protein
204101_at MTM1 myotubularin 1
219534_x_at RMND5B;CDKN1C required for meiotic nuclear division 5 homolog B
1559680_at TTL tubulin tyrosine ligase
207509_s_at LAIR2 leukocyte-associated immunoglobulin-like receptor 2
210196_s_at PSG1 pregnancy specific beta-1-glycoprotein 1
228568_at Gcom1 GRINL1A combined protein
241525_at LOC200772 hypothetical protein LOC200772
1554273_a_at LRAP leukocyte-derived arginine aminopeptidase
1562371_s_at MGC26733 hypothetical protein MGC26733
220646_s_at KLRF1 killer cell lectin-like receptor subfamily F, member 1
203780_at EVA1 epithelial V-like antigen 1
226736_at CHURC1 churchill domain containing
209160_at AKR1C3 aldo-keto reductase family 1, member C3
202458_at PRSS23 protease, serine, 23
207314_x_at KIR3DL2 killer cell immunoglobulin-like receptor, three domains, long
cytoplasmic tail, 2
221670_s_at LHX3 LIM homeobox 3
1557158_s_at MLL3 myeloid/lymphoid or mixed-lineage leukemia 3
203775_at SLC25A13 solute carrier family 25, member 13
207840_at CD160 CD160 molecule
230464_at EDG8 endothelial differentiation, sphingolipid G-protein-coupled
receptor, 8
224036_s_at LMBR1 limb region 1 homolog
207796_x_at KLRD1 killer cell lectin-like receptor subfamily D, member 1
223836_at KSP37 Ksp37 protein
211397_x_at KIR2DL2 killer cell immunoglobulin-like receptor, two domains, long
cytoplasmic tail, 2
228601_at LOC401022 hypothetical LOC401022
1553177_at SH2D1B SH2 domain containing 1B
210354_at IFNG interferon, gamma
207583_at ABCD2 ATP-binding cassette, sub-family D (ALD), member 2
Up-regulation, )2
213096_at TMCC2 transmembrane and coiled-coil domain family 2
205239_at AREG amphiregulin (schwannoma-derived growth factor)
209503_s_at PSMC5 proteasome 26S subunit, ATPase, 5
201605_x_at CNN2 calponin 2
203936_s_at MMP9 Matrixmetallo peptidase 9
211372_s_at IL1R2 interleukin 1 receptor, type II
1555423_at SSH2 Protein phosphatase Slingshot homolog 2
1567287_at OR5K2 Olfactory receptor 5K2
210432_s_at SCN3A Sodium channel, voltage-gated, type III, alpha
206676_at CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8
229961_x_at FLJ44968 FLJ44968
1569481_s_at SNX22 Sorting nexin 22
204438_at MRC1L1;MRC1 Mannose receptor, C type 1-like 1
221152_at COL8A1 Collagen, type VII, alpha 1
213650_at GOLGA8B golgi autoantigen, golgin subfamily a, 8B
205513_at TCN1 transcobalamin I (vitamin B12 binding protein, R binder family)
223821_s_at SUSD4 Sushi domain containing 4
215342_s_at RABGAP1L RAB GTPase activating protein 1-like
216054_x_at MYL4 myosin, light polypeptide 4
219890_at CLEC5A C-type lectin domain family 5, member A
223565_at PACAP Proapoptotic caspase adaptor protein
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(Table 3 continued)
Original source file data
Probe set ID Gene name Describe
223660_at ADORA3 Adenosine A3 receptor
1555199_at GOSR1 Golgi SNAP receptor complex member 1
202286_s_at TACSTD2;CCND1 Tumor-associated calcium signal transducer
210004_at OLR1 Oxidized low density lipoprotein receptor 1
207329_at MMP8 matrix metallopeptidase 8
219478_at WFDC1 WAP four-disulfide core domain 1
207802_at CRISP3 cysteine-rich secretory protein 3
208937_s_at ID1 Inhibitor of DNA binding 1
206177_s_at ARG1 Arginase
207014_at GABRA2 Gamma-aminobutyric acid A receptor, alpha 2
211430_s_at F7;LOC652848 coagulation factor VII
205403_at IL1R2 Interleukin 1 receptor, type II
231790_at DMGDH dimethylglycine dehydrogenase
201324_at EMP1 epithelial membrane protein 1
210712_at LDHAL6B lactate dehydrogenase A-like 6B
1553781_at MGC14289 similar to RIKEN cDNA 1200014N16 gene
204787_at VSIG4 V-set and immunoglobulin domain containing 4
Table 4 Selected markers characterized for their up/down-regulation between different groups.
Marker name Factor Affymetrix HG-U133 plus 2.0 Result from Location
Down-regulated Fold down Probe ID Array fold microarray
AKR1C3 –83.66 209160_at 0.46 consistent 10p15-p14
KIR3DL2 –23.25 207314_x_at 0.47 consistent 19q13.4
SLC25A13 –20.69 203775_at 0.47 consistent 7q21.3
CHURC1 –11.08 226736_at 0.45 consistent 14q23.3
VSIG4 –11.78 204787_at 3.84 inconsistent Xq12-q13.3
MMP8 –11.80 207329_at 2.31 inconsistent 11q22.3
CNN2 –5.99 201605_x_at 2.03 inconsistent 19p13.3
PSMC5 –20.69 209503_s_at 2.02 inconsistent 17q23-q25
Compared with early onset severe preeclampsia, women with normotensive pregnancies have an 83.7-fold increase in AKR1C3,
an 11.1-fold increase in CHURC1, a 23.2-fold increase in KIR3DL2 and a 20.7-fold increase in SLC25A13.
above-mentioned, differentially expressed genes resulted
in a clear separation of the ES-PE from the healthy
controls.
MAS in GenMAPP showed that after correction for
multiple hypothesis testing there were statistically signif-
icant enrichments of transcripts within the 38 genes that
are up-regulated in the ES-PE, displaying extracellular
space (Ps9.0E-6), cell proliferation (Ps0.0016), smooth
muscle contraction (Ps0.01). The over-expressed genes
included CNN2, VSIG4, PSMC5 and MMP8. On the other
hand, statistically significant association of the 34 down-
regulated genes in ES-PE was observed with pathways
such as natural killer cell mediated cytotoxicity (Ps0.00),
antigen processing and presentation (Ps6.3E-5) and
arachidonic acid metabolism (Ps0.05), suggesting
immune response associated with the circulating cells of
ES-PE. The significant down-regulated genes included
KIR3DL2, AKR1C3, CHURC1, SLC25A13.
SYBR green I real-time PCR validation
To further validate the preeclampsia-status classifier
genes, we determined expression levels of the 8 pre-
eclampsia-status classifier genes using the SYBR Green
I real-time PCR methodology on 56 samples for which
enough RNA was available. The initially identified candi-
date genes were assayed by real-time PCR on a sample
set of 32 ES-PE and 24 controls. To control for technical
variation, we performed the comparative Ct method
between a candidate gene and a housekeeping gene
(DCTsCt of target gene–Ct of housekeeping gene,
DDCTsDCT of target gene–DCT of housekeeping gene)
to assess differences between the tested experimental
groups. We found statistically significant differences in
the expression of AKR1C3, KIR3DL2, SLC25A13,
CHURC1 in ES-PE, which selected from the array results.
For CNN2, VSIG4, MMP8 and PSMC5, the findings were
inconsistent with microarray (Table 4). We stress here that
the true specificity of the assay will require the inclusion
of patients with ES-PE pathology other than the disease.
Discussion
It is increasingly evident that a gene plays an important
role in the development of preeclampsia. We report here
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the feasibility of using gene expression profiling of cir-
culating blood cells to identify novel blood biomarker in
ES-PE patients. Our study suggests several points. First,
through a whole-genome gene expression profiling anal-
ysis of cases and controls, we have identified a 4-gene
signature in peripheral blood cells that distinguishes early
onset severe preeclamptic patients from controls. Signif-
icant down-regulation of KIR3DL2, AKR1C3, CHURC1
and SLC25A13 were observed from microarray analysis
and further validated by SYBR Green I realtime RT-PCR
assays. Moreover, this investigation also suggested that
many of the biological pathways such as natural killer cell
mediated cytotoxicity, antigen processing and presenta-
tion and arachidonic acid metabolism have been asso-
ciated with development of preeclampsia. Although our
primary interest was ES-PE, we believe that the approach
shown in our study can be used to identify biomarkers
in other diseases.
Many clinical studies correlated alterations in expres-
sion of individual genes with preeclampsia, often with
contradictory results. Han et al. have report that the
expression of caspase-10 and death receptor 3 (DR-3)
was significantly increased, whereas insulin-like growth
factor binding protein-3 (IGFBP-3) was strongly down-
regulated w5x. Okazaki et al. showed that the mRNA
expression of pregnancy-specific beta1 glycoprotein and
trophoblast glycoprotein is up-regulated in cells circulat-
ing in blood of women with preeclampsia w11x. Surprising-
ly, none of these genes are present in our set of 72
genes. This could be due to the fact that we determine
gene expression at the period of early onset of the dis-
ease, whereas most previous studies did not confine the
time of onset and the origin of samples. Killer cell immu-
noglobulin-like receptors (KIRs) are of particular interest
in the context of preeclampsia. They have been divided
into distinct groups, depending on the number of exter-
nal immunoglobulin domains (2D or 3D). The presence of
a long cytoplasmatic tail with two immune tyrosine-
based inhibitory motifs (ITIMs) allows the transduction of
inhibitory signals and characterizes the inhibitory KIRs
(2DL, 3DL), whereas the presence of short cytoplasmatic
tails corresponds to the activating KIR receptors (2DS,
3DS) w19x. KIRs are glycoproteins expressed on the cell
surface of natural killer (NK) and subsets of T cells. A
well-described way of NK cells to recognize target cells
is surveillance for cells with reduced levels of MHC class
I molecules, a phenotypic change that frequently occurs
in tumor variants and virally infected cells. Different
inhibitory KIRs are specific for HLA-A (KIR3DL2),
HLA-B (KIR3DL1), and different subgroups of HLA-C
(KIR2DL1–3). Defective placentation is the likely patho-
genesis of preeclampsia w10x. This involves reduced
trophoblast invasion into both the decidua and spiral
arteries. The loose plugs of endovascular trophoblast
that normally limit the maternal circulation to the placenta
may be incomplete w8x. The correlation between the
development of ES-PE and primigravidae is suggestive
of a defect in fetal–maternal immune recognition. Our
work provides molecular evidence that this immune
problem may be mediated by defective KIR3DL2 expres-
sion. We observed reduced KIR3DL2 transcription levels
in ES-PE and propose that lacking killer-inhibitory recep-
tors for self-HLA class I molecules results in abnormal
activation of NK/T cells, weaken inhibitory signaling,
powering NK cells recognition. Trophoblasts lacking
KIR3DL2 are vulnerable to attack by the maternal
immune system, thereby developing vessels which can-
not adequately nourish the developing placenta.
Aldo-Keto Reductases (AKRs) are a superfamily of
NAD(P)H linked oxidoreductases that catalyze the
NADP(H)-dependent reduction of a wide variety of sub-
strates. AKR1C3 possesses 3a-HSD, 17b-HSD, 20a-
HSD and prostaglandin (PG) F synthase activities and
catalyzes androgen, estrogen, progesterone and PG
metabolism w13x. AKR1C3, therefore, has the capability
of regulating ligand access to multiple nuclear receptors
including the androgen receptor (AR), estrogen receptor,
progesterone receptor and peroxisome proliferators acti-
vated receptor gamma (PPARg) in endocrine peripheral
tissues. AKR1C3 may prevent PPARg signaling by pre-
venting the formation of its ligand 15d-PGJ2 and by stim-
ulating the phosphorylation of the receptor, leading to a
pro-proliferative response. AKR1C3 is uniquely posi-
tioned to reduce PGH2 and PGD2 to yield PGF epimers
leading to the inactivation of PPARg upon exposure to
oxidative stress. Moreover, since the PGF epimers bind
to the F-series-prostanoid (FP) receptor, this could lead
to activation of NFkB and propagation of an inflammatory
response involving induction of COX-2. Severe Deoxy-
corticosterone (DOC) excess as is seen in 17a- and 11b-
hydroxylase deficiencies causes hypertension, and
moderate DOC overproduction in late pregnancy is asso-
ciated with hypertension. Excess DOC will bind to the
mineralocorticocoid receptor causing hypertension in
pregnancy when AKR1C3 decreases w16x. AKR1C3 pro-
tects the mineralocorticoid receptor from activation by
DOC in mineralocorticoid target cells of the kidney and
colon. Oxidative stress may mediate endothelial cell dys-
function and contribute to the pathophysiology of pre-
eclampsia as there is evidence of increased prooxidant
activity formation along with decreased antioxidant pro-
tection preeclampsia. Higher placental NADPH oxidase
activity has been reported in women with early-onset
preeclampsia as compared with those with late-onset
of disease which is consistent with the concept that early-
onset preeclampsia is more dependent on placental dys-
function than the later-onset disease. Down-regulated
AKR1C3 expression in maternal blood may result in lack-
ing of anti-oxidant response elements, therefore, reactive
oxygen species produced under conditions of oxidative
stress, attack polyunsaturated fatty acids to form a series
of lipid peroxides which are implicated in the patho-
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genesis of atherosclerotic plaques. The lipid peroxides
further damage the structure and function of vascular
endothelial cell.
No biological function of Churchill (ChCh) in relation to
preeclampsia is known to date. ChCh is a zinc-containing
protein involved in neural induction during embryogene-
sis. ChCh was discovered in a differential screen for neu-
ral inducing factors present in chick embryos w9x. ChCh
was identified as a late FGF response gene that is up-
regulated within 4–5 h of signaling from both the organ-
izer and FGF and shows no indication of down-regulation
in the presence of BMP. It is difficult to speculate on
a preeclampsia-promoting function of CHURC1. Zinc
finger proteins are known to participate in a variety of
cellular activities including development, differentiation,
and tumor suppression and though originally determined
to be DNA binding proteins, there is increasing evidence
that zinc finger proteins also recognize RNA and partici-
pate in protein-protein and protein-lipid interactions.
The SLC25A13 gene consists of 18 exons and
encodes a liver type mitochondrial aspartate-glutamate
carrier named citrin, which plays an important role in
malate-aspartate NADH shuttling, urea synthesis, and
gluconeogenesis. In humans, loss-of-function mutations
in the SLC25A13 gene encoding citrin cause both adult-
onset type II citrullinemia (CTLN2) and neonatal intrahe-
patic cholestasis (NICCD), collectively referred to as
human citrin deficiency w17x. The urea cycle processes
excess nitrogen to make urea, which is excreted in urine.
An adequate supply of aspartate must be transported out
of mitochondria to participate in a process called the urea
cycle which is a sequence of chemical reactions that
takes place in liver cells. These reactions process excess
nitrogen that is generated as the body uses proteins.
Research reveals that loss of citrin first causes deficiency
of aspartate in the cytosol, which results in an increase
in cytosolic NADH/NAD(q) ratio and then activation of
fatty acid synthesis pathway to compensate the aberrant
ratio w14x. SLC25A13 expression is down-regulated in the
ES-PE. As a result of citrin deficiency, arginine cannot
be supplied from the urea cycle which is the enzyme-
substrate complex of endothelia nitric oxide synthase
(eNOS), therefore, nitrogen monoxidum cannot generate
enough from eNOS.
The VSIG4, CNN2, MMP8 and PSMC5 yielded incon-
sistent results. For VSIG4, discordant observations
between the array hybridization (up 3.84-fold) and real-
time PCR (significantly down 12-fold, Ps0.003) were
made for ES-PE. We have also observed, in the microar-
ray, 2-fold up-regulations were for CNN2, 2.3-fold for
MMP8 and 2-fold for PSMC5. In quantitative PCR, how-
ever, we found a significantly decreased expression level.
From these data, we have identified AKR1C3, CHURC1,
SLC25A13 and KIR3DL2 which might be involved in the
molecular mechanisms underlying the progression of
ES-PE, and highlight potential targets for therapeutic
intervention.
Acknowledgements
The authors would like to thank the participants of the study.
This study was supported by the National Natural Science Foun-
dation of China (The Grant No. is 30672238).
References
w1x American College of Obstetricians and Gynecologists.
Diagnosis and management of preeclampsia, and eclamp-
sia. Obstet Gynecol. 2002;99:159–68.
w2x Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-
eclampsia and risk of cardiovascular disease and cancer
in later life: systematic review and meta-analysis. Br Med
J. 2007;335:974.
w3x Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M,
Thom E, et al. Low-dose aspirin to prevent preeclampsia
in women at high risk. National Institute of Child Health
and Human Development Network of Maternal-fetal Med-
icine Units. N Engl J Med. 1998;338:701–5.
w4x Gaugler-Senden IP, Berends AL, de Groot CJ, Steegers
EA. Severe, very early onset preeclampsia: subsequent
pregnancies and future parental cardiovascular health. Eur
J Obstet Gynecol Reprod Biol. 2008;140:171–7.
w5x Han JY, Kim YS, Cho GJ, Roh GS, Kim HJ, Choi WJ, et
al. Altered gene expression of caspase-10, death receptor-
3 and IGFBP-3 in preeclamptic placentas. Mol Cells. 2006
31;22:168–74.
w6x Han M, Liew CT, Zhang HW, Chao S, Zheng R, Yip KT,
et al. Novel blood-based, five-gene biomarker set for the
detection of colorectal cancer. Clin Cancer Res. 2008;
14:455–60.
w7x Ho¨gberg U. The World Health Report 2005: ‘‘make every
mother and child count’’ – including Africans. Scand J
Public Health. 2005;33:409–11.
w8x Hustin J, Jauniaux E, Schaaps JP. Histological study of the
materno-embryonic interface in spontaneous abortion.
Placenta. 1990;11:477–86.
w9x Leptin M. Gastrulation movements: the logic and the nuts
and bolts. Dev Cell. 2005;8:305–20.
w10x Norwitz ER. Defective implantation and placentation:
laying the blueprint for pregnancy complications. Reprod
Biomed Online. 2006;13:591–9.
w11x Okazaki S, Sekizawa A, Purwosunu Y, Farina A, Wibowo
N, Okai T. Placenta-derived, cellular messenger RNA
expression in the maternal blood of preeclamptic women.
Obstet Gynecol. 2007;110:1130–6.
w12x Pang ZJ, Xing FQ. DNA microarrays detect the expression
of apoptosis-related genes in preeclamptic placentas.
J Perinat Med. 2004;32:25–30.
w13x Penning TM, Burczynski ME, Jez JM, Lin HK, Ma H, Moore
M, et al. Structure-function aspects and inhibitor design of
type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
Mol Cell Endocrinol. 2001;171:137–49.
w14x Saheki T, Kobayashi K, Iijima M, Moriyama M, Yazaki M,
Takei Y, et al. Metabolic derangements in deficiency of
citrin, a liver-type mitochondrial aspartate-glutamate
carrier. Hepatol Res. 2005;33:181–4.
w15x Sato K. A proposal for a new definition and classification
of ‘‘Pregnancy Induced Hypertension (PIH)’’ (2004), in
Japan Society for the Study of Toxemia of Pregnancy (ed):
Historical Perspective of Study of Pregnancy-Induced
616 Sun et al., Gene expression profiling of early onset severe preeclampsia
Article in press - uncorrected proof
Hypertension in Japan. Tokyo, Medical View Co, 2005:
pp. 54–87.
w16x Sharma KK, Lindqvist A, Zhou XJ, Auchus RJ, Penning
TM, Andersson S. Deoxycorticosterone inactivation by
AKR1C3 in human mineralocorticoid target tissues. Mol
Cell Endocrinol.2006;248:79–86.
w17x Tabata A, Sheng JS, Ushikai M, Song YZ, Gao HZ, Lu YB,
et al. Identification of 13 novel mutations including a retro-
transposal insertion in SLC25A13 gene and frequency of
30 mutations found in patients with citrin deficiency.
J Hum Genet. 2008;53:534–45.
w18x Talbi S, Hamilton AE, Vo KC, Tulac S, Overgaard MT,
Dosiou C, et al. Molecular phenotyping of human endo-
metrium distinguishes menstrual cycle phases and under-
lying biological processes in normo-ovulatory women.
Endocrinology. 2006;147:1097–121.
w19x Yawata M, Yawata N, Abi-Rached L, Parham P. Variation
within the human killer cell immunoglobulin-like receptor
(KIR) gene family. Crit Rev Immunol. 2002;22:463–82.
The authors stated that there are no conflicts of interest regard-
ing the publication of this article.
Received December 27, 2008. Revised March 18, 2009.
Accepted May 4, 2009. Previously published online August 17,
2009.
